Skip to Main content Skip to Navigation
New interface
Journal articles

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

Abstract : Abstract CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86–95] in low-risk vs. 79% [95%CI 75–84] in high-risk, p = 1.04E−02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients’ stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype.
Document type :
Journal articles
Complete list of metadata
Contributor : François Bertucci Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 2:25:44 PM
Last modification on : Friday, April 1, 2022 - 3:52:41 AM

Links full text




Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, F. Bertucci. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. npj Breast Cancer, 2021, 7 (1), pp.48. ⟨10.1038/s41523-021-00256-2⟩. ⟨hal-03623055⟩



Record views